Doctors embrace drug touted by Trump for Covid-19


Left: A woman holds a hydroxychloroquine prescription in Seattle, Washington, U.S. March 31, 2020. Right: U.S. President Donald Trump stops a reporter from asking Dr. Anthony Fauci a question about use of the drug hydroxychloroquine to treat the disease caused by the new coronavirus near the end of the daily coronavirus task force briefing at the White House in Washington, U.S., April 5, 2020. - Reuters

NEW YORK/LOS ANGELES: The decades-old drug that President Donald Trump has persistently promoted as a potential weapon against COVID-19 has within a matter of weeks become a standard of care in areas of the United States hit hard by the pandemic — though doctors prescribing it have no idea whether it works.

Doctors and pharmacists from more than half a dozen large healthcare systems in New York, Louisiana, Massachusetts, Ohio, Washington and California told Reuters they are routinely using hydroxychloroquine on patients hospitalized with COVID-19.

At the same time, several said they have seen no evidence that the drug, used for years to treat malaria and autoimmune disorders, has any effect on the virus.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Powering on data centres
Medical insurance premiums on the rise
Kelington to reap the benefits of a diversified business strategy
Rising data centre ability
Making scents of success
Investors brace for 5% Treasury yields
Are there too many GPs and is the healthcare system overwhelmed?
Sapura Energy takes a step to turn the tide
Japan frets over relentless yen slide as BoJ keeps ultra-low rates
Singapore’s growth trajectory remains intact

Others Also Read